Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) saw strong trading volume on Friday . 659,897 shares traded hands during trading, an increase of 141% from the previous session’s volume of 273,430 shares.The stock last traded at $15.07 and had previously closed at $14.36.

A number of analysts have recently issued reports on the company. Mizuho lifted their price target on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Thursday, April 28th. Noble Financial assumed coverage on Adamas Pharmaceuticals in a research report on Friday, June 17th. They set a “buy” rating and a $25.00 price target for the company. Credit Suisse Group AG reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. JMP Securities reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $44.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $32.00.

The firm’s 50 day moving average is $15.69 and its 200 day moving average is $16.11. The company’s market capitalization is $326.57 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.11. Analysts forecast that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current fiscal year.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP increased its position in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned approximately 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent reporting period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.